Comparative Pharmacology
Head-to-head clinical analysis: ISOTRETINOIN versus ZENATANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOTRETINOIN versus ZENATANE.
ISOTRETINOIN vs ZENATANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reduces sebum production, inhibits sebaceous gland activity, and induces apoptosis in sebocytes. Binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs) to regulate gene expression.
Isotretinoin (13-cis-retinoic acid) reduces sebaceous gland size and inhibits sebum production by binding to nuclear retinoic acid receptors (RARs and RXRs), altering gene expression involved in cell differentiation and apoptosis.
0.5-1 mg/kg/day orally in two divided doses for 15-20 weeks; cumulative dose 120-150 mg/kg.
0.5 mg/kg orally once daily, titrated up to 1 mg/kg/day based on response; maximum 2 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 10-30 hours) for the parent drug. Clinical significance: steady-state achieved in ~5 days with repeated dosing; prolongation in renal impairment is minimal.
Clinical Note
moderateIsotretinoin + Estrone sulfate
"The therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Estramustine
"The therapeutic efficacy of Estramustine can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Dienogest
"The therapeutic efficacy of Dienogest can be decreased when used in combination with Isotretinoin."
Clinical Note
moderateIsotretinoin + Medroxyprogesterone acetate
Terminal elimination half-life is 16-22 hours (mean 19 hours) in adults. Steady-state achieved in 3-5 days. Half-life may be prolonged up to 40 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism; metabolites excreted in urine (65-80%) and feces (15-35%). Less than 1% excreted unchanged in urine.
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (10-20%). Fecal elimination accounts for 10-15% via biliary secretion.
Category D/X
Category C
Retinoid
Retinoid
"The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin."